DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
The Orphan Drug Act Turns 40: NORD Celebrates Its Impact on Rare Diseases
Individuals suffering with rare diseases had very few therapeutic options 40 years ago. But that began to change with the stroke of a pen by then-President Ronald Reagan in January 1983 when he signed the bipartisan Orphan Drug Act into law. On Jan. 4, the rare disease community will celebrate the 40th anniversary of the Orphan Drug Act (ODA) — legislation that incentivized drug companies to put more resources toward the research, development, and distribution of therapeutics for people with rare diseases, who until then had been ‘orphaned’ by the medical and scientific community.
The creation of the ODA and the founding of the National Organization for Rare Disorders (NORD) are forever intertwined. The rare patients and caregivers who started the rare advocacy movement — which convinced lawmakers to introduce orphan drug legislation — knew their work was not done after the bill became law. They formed NORD to unify the voices of the unheard within the rare disease community under the premise that a rising tide could lift all boats.
Related Content
-
education & researchMulticenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation th...BACKGROUND: Over the past few decades, l...
-
people & placesEdward J. Benz Jr., MDDr. Benz graduated from Harvard Medical ...
-
education & researchPerioperative considerations for patients with sickle cell disease: a narrative reviewPURPOSE: Approximately 200,000 individua...
-
news & eventsA Britain’s Got Talent contestant revealed how she turned to singing following the death of her sonA Britain's Got Talent contestant whose ...
-
Community CenterLiving With Unpredictable Pain: A Sickle Cell Disease StoryGrowing up, Vismel Marquez wanted to joi...
-
videos & visualsSickle Cell Patient Finds a Better way of Living Through Apheresishttps://www.youtube.com/watch?v=BSTUaeFz...
-
news & eventsIndiana Sickle Cell Disease Conference by The Martin CenterThis one day 2018 Indiana Sickle Cell Di...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.